

Ref. No: 2724
Date: 31/07/26
Subject: Treatment with immunology medicines(Gastroenterology)

REQUEST & RESPONSE

I would be grateful if you could tell me how many patients were treated in the 3 months between April and June 2026 for the list of drugs named in the questions below.

Please fill in the template below with the number of patients or a format of your choice. Please include data for all hospitals in your organisation.

Q1. How many patients were treated in **total** regardless of diagnosis with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

Drug Name	<u>Total</u> number of patients treated <u>regardless of diagnosis</u>
Adalimumab	316
Etrasimod	0
Filgotinib	<5
Golimumab	13
Guselkumab	14
Infliximab	95
Mirikizumab	12
Ozanimod	0
Risankizumab	34
Tofacitinib	<5
Upadacitinib	25
Ustekinumab	56
Vedolizumab	60

Q2. How many patients were treated by the **Gastroenterology** Department or Clinic with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

Drug Name	Number of patients treated by the Gastroenterology Department
Adalimumab	41
Etrasimod	0
Filgotinib	0
Golimumab	<5
Guselkumab	0
Infliximab	78
Mirikizumab	11
Ozanimod	0
Risankizumab	8
Tofacitinib	<5
Upadacitinib	11
Ustekinumab	40
Vedolizumab	58

Q3. How many patients with **Crohn's Disease**, **Ulcerative Colitis** or **Inflammatory Bowel Disease NOS** in total regardless of department / clinic, were treated with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

Drug Name	Number patients with Crohn's Disease	Number patients with Ulcerative Colitis	Number patients with Inflammatory Bowel Disease NOS
Adalimumab			
Etrasimod			
Filgotinib			
Golimumab			
Guselkumab			
Infliximab			
Mirikizumab			
Ozanimod			
Risankizumab			
Tofacitinib			
Upadacitinib			
Ustekinumab			

Vedolizumab			
-------------	--	--	--

Pharmacy do not keep diagnosis information for Q3 so are unable to answer.